biotech · PIK3CA Mutation · PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation · RLAY
Relay Therapeutics
Relay Therapeutics clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Cambridge, USA HQ
2016 Founded
211 Employees
Public company Type
RLAY · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2016
- Employees
- 211
- Programs
- 6
- Drugs
- 7
- Patents
- 12
Relay Therapeutics projects
2 ClinicalTrials.gov programs sponsored by Relay Therapeutics.
Relay Therapeutics has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
Frequently asked questions
How many clinical projects does Relay Therapeutics have?
2 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.